TD Cowen analyst Joseph Thome maintained a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report) today. The company’s shares opened today at $16.11.
Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, Chimerix, and PTC Therapeutics. According to TipRanks, Thome has an average return of -13.6% and a 29.31% success rate on recommended stocks.
Currently, the analyst consensus on Entrada Therapeutics Inc is a Moderate Buy with an average price target of $25.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $21.64 and a one-year low of $9.32. Currently, Entrada Therapeutics Inc has an average volume of 44.95K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Entrada Therapeutics Inc (TRDA) Company Description:
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Read More on TRDA:
